Theracryf Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Huw Jones

Chief Executive Officer (CEO)

UK£302.9k

Compensación total

Porcentaje del salario del CEO	71.0%
Permanencia del CEO	4.1yrs
Participación del CEO	0.7%
Permanencia media de la dirección	3.5yrs
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Oct 11

We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely

Nov 24

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Aug 06

Is Evgen Pharma (LON:EVG) In A Good Position To Deliver On Growth Plans?

Apr 09

We're Keeping An Eye On Evgen Pharma's (LON:EVG) Cash Burn Rate

Dec 25

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Huw Jones en comparación con los beneficios de Theracryf?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	UK£303k	UK£215k	-UK£3m
Dec 31 2023	n/a	n/a	-UK£3m
Sep 30 2023	n/a	n/a	-UK£3m
Jun 30 2023	n/a	n/a	-UK£4m
Mar 31 2023	UK£305k	UK£200k	-UK£4m
Dec 31 2022	n/a	n/a	-UK£4m
Sep 30 2022	n/a	n/a	-UK£3m
Jun 30 2022	n/a	n/a	-UK£3m
Mar 31 2022	UK£240k	UK£188k	-UK£3m
Dec 31 2021	n/a	n/a	-UK£3m
Sep 30 2021	n/a	n/a	-UK£2m
Jun 30 2021	n/a	n/a	-UK£3m
Mar 31 2021	UK£224k	UK£88k	-UK£3m

Compensación vs. Mercado: La compensación total ($USD379.54K) de Huw está en línea con el promedio de empresas de tamaño similar en el mercado UK ($USD354.03K).

Compensación vs. Ingresos: La compensación de Huw ha sido consistente con los resultados de la empresa en el último año.

CEO

Huw Jones (65 yo)

4.1yrs

Permanencia

UK£302,890

Compensación

Dr. Huw Jones, BSc, Ph D., serves as Non-Executive Director of Ixaka Limited since August 2023. He serves as Chief Executive Officer at Theracryf Plc (formerly known as Evgen Pharma plc) since October 1, 2...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Huw Jones	CEO & Executive Director	4.1yrs	UK£302.89k	0.74% £ 17.1k
Toni Haenninen	CFO & Director	1.2yrs	UK£385.25k	0.23% £ 5.4k
Helen Kuhlman	Chief Business Officer	3.6yrs	sin datos	0.25% £ 5.7k
Glen Clack	Chief Medical Officer	3.5yrs	sin datos	0.23% £ 5.4k

3.5yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de TCF se considera experimentado (3.5 años antigüedad media).

Theracryf Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Less than half of directors are independent

Theracryf Plc Announces Demise of Sue Foden, Chair

Theracryf Plc, Annual General Meeting, Jul 18, 2024

Evgen Pharma plc Appoints Toni hänninen as Permanent Chief Financial Officer, Effective 1 January 2024

Evgen Pharma plc Announces Executive Changes

Evgen Pharma plc, Annual General Meeting, Jul 20, 2023

Recent updates

Theracryf Plc to Report First Half, 2025 Results on Nov 28, 2024

Less than half of directors are independent

Theracryf Plc Announces Demise of Sue Foden, Chair

New major risk - Share price stability

Theracryf Plc, Annual General Meeting, Jul 18, 2024

Theracryf Plc to Report Fiscal Year 2024 Results on May 28, 2024

New minor risk - Financial data availability

Evgen Pharma plc has completed a Follow-on Equity Offering in the amount of £0.05167 million.

Evgen Pharma plc has filed a Follow-on Equity Offering in the amount of £1 million.

Evgen Pharma plc Announces That the Laboratories of Professor Grace Chen, Associate Professor Justin Colacino, and Professor Duxin Sun At the University of Michigan, Usa Have Observed Activity of Sfx-01 in Models of Colon Cancer

Evgen Pharma plc Announces That the Laboratory of Dr Marjolein Geurts, Neuro-Oncologist At the Erasmus University Medical Centre Has Observed Continuing Activity of Sfx-01 in Gbm Cells

Evgen Pharma plc announced that it has received $17.4 million in funding from Stalicla SA

New minor risk - Share price stability

Evgen Pharma plc Appoints Toni hänninen as Permanent Chief Financial Officer, Effective 1 January 2024

Evgen Pharma plc Announces Erasmus Medical Center Commences Sfx-01 Glioblastoma Studies

Evgen Pharma plc Announces Executive Changes

Evgen Pharma plc Announces Final Clinical Study Report from Phase 1B PK/PD Study of New SFX-01 Tablet Formulation Approved

New major risk - Market cap size

New minor risk - Share price stability

Evgen Pharma plc, Annual General Meeting, Jul 20, 2023

Consensus revenue estimates fall by 92%

Evgen Pharma plc to Report Q4, 2023 Results on Jun 07, 2023

Evgen Pharma plc Announces Update on Study to Investigate Performance of New SFX-01 Tablet Formulation - All Cohorts Dosed

Consensus forecasts updated

Evgen Pharma plc to Report First Half, 2023 Results on Dec 08, 2022

Insufficient new directors

Evgen Pharma plc Announces Clinical Trial Update

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Evgen Pharma plc Receives Regulatory and Ethical Approvals for A Healthy Volunteer, Pharmacokinetic and Pharmacodynamic, Study Toexamine the Performance of the Company's New Enteric Coated Tablet Formulation of Lead Asset SFX-01

Evgen Pharma plc, Annual General Meeting, Jul 21, 2022

Evgen Pharma plc to Report Fiscal Year 2022 Results on Jun 08, 2022

Insufficient new directors

Evgen Pharma plc Announces Progress Discussions with the UK Medicines and Healthcare Products Regulatory Agency and the US Food and Drug Administration

Insufficient new directors

We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Evgen Pharma plc Announces Early Data for SFX-01 in Leukaemia Cell Lines

Evgen Pharma plc Announces Glioma Orphan Drug Application Submitted to US FDA

Evgen Pharma plc Announces Progress on Metastatic Breast Cancer Programme

Is Evgen Pharma (LON:EVG) In A Good Position To Deliver On Growth Plans?

Evgen Pharma plc Provides Update on Data Safety Review for STAR COVID-19 Trial

Evgen Pharma plc Updates on Patient Recruitment

Evgen Pharma plc, Annual General Meeting, Mar 03, 2021

We're Keeping An Eye On Evgen Pharma's (LON:EVG) Cash Burn Rate

Evgen Pharma plc to Report Fiscal Year 2020 Results on Jun 15, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media